reference/18194391

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18194391

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
issn	0025-7974
issueIdentifier	23
pageRange	e958-
publicationName	Medicine
startingPage	e958
bibliographicCitation	Du F, Zheng Z, Shi S, Jiang Z, Qu T, Yuan X, Sun Y, Song Y, Yang L, Zhao J, Wang J, Chi Y. S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial. Medicine (Baltimore). 2015 Jun;94(23):e958. PMID: 26061330; PMCID: PMC4616475.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c476ee82d1dbd94a5bcd059ffa632c79 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7102b390210b1903e78e371e2b2bb34e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b0c691fb4dfcaaba869533efb7166f3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4ec353310d5296e5c01bf6bcb23cf57a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_48afe4075a73e94ec2959fd08d935b3d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fdf2dcc3934936660bfdb45e7c76d0be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8dc4a76e9d9f80c863e109afec2fb5c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98e9b06bfdf41d250c95f90660fa30b9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ac9eed2934ee4cdf4ce25226f6403ff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81e7c42d0f8819297cd87ad8b46c5a41 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05110da2b46d93d6f636169e4d709060
date	201506
identifier	https://doi.org/10.1097/md.0000000000000958 https://pubmed.ncbi.nlm.nih.gov/26061330 https://pubmed.ncbi.nlm.nih.gov/PMC4616475
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5748 https://portal.issn.org/resource/ISSN/0025-7974
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
discusses	http://id.nlm.nih.gov/mesh/M0212066 http://id.nlm.nih.gov/mesh/M0008871 http://id.nlm.nih.gov/mesh/M0006823 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0486221 http://id.nlm.nih.gov/mesh/M0004505 http://id.nlm.nih.gov/mesh/M0001471 http://id.nlm.nih.gov/mesh/M0015657
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D005641Q000008 http://id.nlm.nih.gov/mesh/D000964Q000008 http://id.nlm.nih.gov/mesh/D010094Q000008 http://id.nlm.nih.gov/mesh/D013274Q000556 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D002945Q000008 http://id.nlm.nih.gov/mesh/D013274Q000188 http://id.nlm.nih.gov/mesh/D061067Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D011446 http://id.nlm.nih.gov/mesh/D004338 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9305 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31398 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198

Total number of triples: 64.